Top

Published in:

01-01-2019 | Systematic Review

Systematic Literature Review of the Economic Burden of Celiac Disease

Authors: Elizabeth S. Mearns, Aliki Taylor, Talia Boulanger, Kelly J. Craig, Michele Gerber, Daniel A. Leffler, Jennifer Drahos, David S. Sanders, Benjamin Lebwohl

Published in: PharmacoEconomics | Issue 1/2019

Abstract

Background

The prevalence of celiac disease (CD) has rapidly increased over recent decades, but costs related to CD remain poorly quantified.

Objective

This systematic review assessed the economic burden of CD in North America and Europe.

Methods

MEDLINE, EMBASE, EconLit, and the Cochrane Library databases were systematically searched to identify English-language literature from 2007 to 2018 that assessed costs, cost effectiveness, and health resource utilization for CD.

Results

Forty-nine studies met the inclusion criteria, of which 28 (57.1%) addressed costs of testing and diagnosis; 33 (67.3%) were from Europe. The cost per positive CD diagnosis of testing patients already undergoing esophagogastroduodenoscopy for other indications ranged from 1300 Canadian dollars ($Can) in Canada (2016 value) to €44,712 in the Netherlands (2013 value). Adding the CD test was cost effective when it combined diagnostic modalities (e.g., serology and biopsy). Direct annual excess costs to a US payer per diagnosed CD patient totaled $US6000 (2013 value) more than for a person without CD, chiefly due to outpatient care. Hospitalizations, emergency visits, and medication use were more common with CD. After initiating a gluten-free diet (GFD), patients visited primary care providers less often, used more medications, and missed fewer days from school and work.

Conclusions

Most of the few available economic studies of CD assess testing and diagnosis costs, especially in Europe. Methods of testing generally are considered cost effective when they combine diagnostic modalities in symptomatic patients. Most costs to a payer of managing CD derive from outpatient care. Following GFD initiation, patients lose fewer days from work and school than pretreatment.

Available only for authorised users

Molberg O, McAdam S, Lundin KE, Kristiansen C, Arentz-Hansen H, Kett K, et al. T cells from celiac disease lesions recognize gliadin epitopes deamidated in situ by endogenous tissue transglutaminase. Eur J Immunol. 2001;31(5):1317–23. https://doi.org/10.1002/1521-4141(200105)31:5%3c1317:AID-IMMU1317%3e3.0.CO;2-I.CrossRefPubMed

Tonutti E, Bizzaro N. Diagnosis and classification of celiac disease and gluten sensitivity. Autoimmun Rev. 2014;13(4–5):472–6. https://doi.org/10.1016/j.autrev.2014.01.043.CrossRefPubMed

Lebwohl B, Ludvigsson JF, Green PH. Celiac disease and non-celiac gluten sensitivity. BMJ. 2015;351:h4347. https://doi.org/10.1136/bmj.h4347.CrossRefPubMedPubMedCentral

Lionetti E, Catassi C. The role of environmental factors in the development of celiac disease: what is new? Diseases. 2015;3:282–93.CrossRef

Catassi C, Gatti S, Fasano A. The new epidemiology of celiac disease. J Pediatr Gastroenterol Nutr. 2014;59(suppl 1):S7–9. https://doi.org/10.1097/01.mpg.0000450393.23156.59.CrossRefPubMed

Ludvigsson JF, Leffler DA, Bai JC, Biagi F, Fasano A, Green PH, et al. The Oslo definitions for coeliac disease and related terms. Gut. 2013;62(1):43–52. https://doi.org/10.1136/gutjnl-2011-301346.CrossRefPubMed

Jericho H, Sansotta N, Guandalini S. Extraintestinal manifestations of celiac disease: effectiveness of the gluten-free diet. J Pediatr Gastroenterol Nutr. 2017;65(1):75–9. https://doi.org/10.1097/MPG.0000000000001420.CrossRefPubMed

Green PH. The many faces of celiac disease: clinical presentation of celiac disease in the adult population. Gastroenterology. 2005;128(4 suppl 1):S74–8.CrossRef

Rampertab SD, Pooran N, Brar P, Singh P, Green PH. Trends in the presentation of celiac disease. Am J Med. 2006;119(4):355 e9–14. https://doi.org/10.1016/j.amjmed.2005.08.044.CrossRef

10.

Rubio-Tapia A, Hill ID, Kelly CP, Calderwood AH, Murray JA. ACG clinical guidelines: diagnosis and management of celiac disease. Am J Gastroenterol. 2013;108(5):656–76. https://doi.org/10.1038/ajg.2013.79.CrossRefPubMedPubMedCentral

11.

Leffler DA, Green PH, Fasano A. Extraintestinal manifestations of coeliac disease. Nat Rev Gastroenterol Hepatol. 2015;12(10):561–71. https://doi.org/10.1038/nrgastro.2015.131.CrossRefPubMed

12.

Hershcovici T, Leshno M, Goldin E, Shamir R, Israeli E. Cost effectiveness of mass screening for coeliac disease is determined by time-delay to diagnosis and quality of life on a gluten-free diet. Aliment Pharmacol Ther. 2010;31(8):901–10. https://doi.org/10.1111/j.1365-2036.2010.04242.x.CrossRefPubMed

13.

Mohseninejad L, Feenstra T, van der Horst HE, Woutersen-Koch H, Buskens E. Targeted screening for coeliac disease among irritable bowel syndrome patients: analysis of cost-effectiveness and value of information. Eur J Health Econ. 2013;14(6):947–57. https://doi.org/10.1007/s10198-012-0441-4.CrossRefPubMed

14.

Chang M, Green PH. Genetic testing before serologic screening in relatives of patients with celiac disease as a cost containment method. J Clin Gastroenterol. 2008;43(1):43–50. https://doi.org/10.1097/MCG.0b013e318187311d.CrossRef

15.

Health Quality O. Clinical utility of serologic testing for celiac disease in ontario: an evidence-based analysis. Ont Health Technol Assess Ser. 2010;10(21):1–111.

16.

Guandalini S, Tundia N, Thakkar R, Macaulay D, Essenmacher K, Fuldeore M. Direct costs in patients with celiac disease in the USA: a retrospective claims analysis. Dig Dis Sci. 2016;61(10):2823–30. https://doi.org/10.1007/s10620-016-4219-x.CrossRefPubMed

17.

Ukkola A, Kurppa K, Collin P, Huhtala H, Forma L, Kekkonen L, et al. Use of health care services and pharmaceutical agents in coeliac disease: a prospective nationwide study. BMC Gastroenterol. 2012;12:136. https://doi.org/10.1186/1471-230x-12-136.CrossRefPubMedPubMedCentral

18.

Mattila E, Kurppa K, Ukkola A, Collin P, Huhtala H, Forma L, et al. Burden of illness and use of health care services before and after celiac disease diagnosis in children. J Pediatr Gastroenterol Nutr. 2013;57(1):53–6.CrossRef

19.

Missbach B, Schwingshackl L, Billmann A, Mystek A, Hickelsberger M, Bauer G, et al. Gluten-free food database: the nutritional quality and cost of packaged gluten-free foods. PeerJ. 2015;3:e1337. https://doi.org/10.7717/peerj.1337.CrossRefPubMedPubMedCentral

20.

Burden M, Mooney PD, Blanshard RJ, White WL, Cambray-Deakin DR, Sanders DS. Cost and availability of gluten-free food in the UK: in store and online. Postgrad Med J. 1081;2015(91):622–6. https://doi.org/10.1136/postgradmedj-2015-133395.CrossRef

21.

Leffler DA, Dennis M, Hyett B, Kelly E, Schuppan D, Kelly CP. Etiologies and predictors of diagnosis in nonresponsive celiac disease. Clin Gastroenterol Hepatol. 2007;5(4):445–50. https://doi.org/10.1016/j.cgh.2006.12.006.CrossRefPubMed

22.

van Gils T, Nijeboer P, van Wanrooij RL, Bouma G, Mulder CJ. Mechanisms and management of refractory coeliac disease. Nat Rev Gastroenterol Hepatol. 2015;12(10):572–9. https://doi.org/10.1038/nrgastro.2015.155.CrossRefPubMed

23.

Violato M, Gray A, Papanicolas I, Ouellet M. Resource use and costs associated with coeliac disease before and after diagnosis in 3,646 cases: results of a UK primary care database analysis. PLoS One. 2012;7(7):e41308. https://doi.org/10.1371/journal.pone.0041308.CrossRefPubMedPubMedCentral

24.

Norstrom F, Sandstrom O, Lindholm L, Ivarsson A. A gluten-free diet effectively reduces symptoms and health care consumption in a Swedish celiac disease population. BMC Gastroenterol. 2012;12:125. https://doi.org/10.1186/1471-230x-12-125.CrossRefPubMedPubMedCentral

25.

Gili M, Béjar L, Ramírez G, López J, Cabanillas JL, Sharp B. Celiac disease and alcohol use disorders: increased length of hospital stay, overexpenditures and attributable mortality. Rev Esp Enferm Dig. 2013;105(9):537–43.CrossRef

26.

Canova C, Pitter G, Ludvigsson JF, Romor P, Zanier L, Zanotti R, et al. Risks of hospitalization and drug consumption in children and young adults with diagnosed celiac disease and the role of maternal education: a population-based matched birth cohort study. BMC Gastroenterol. 2016;16:1. https://doi.org/10.1186/s12876-015-0415-y.CrossRefPubMedPubMedCentral

27.

Roos S, Wilhelmsson S, Hallert C. Swedish women with coeliac disease in remission use more health care services than other women: a controlled study. Scand J Gastroenterol. 2011;46(1):13–9.CrossRef

28.

Skef W, Koulouridis I, Gonzalez A. National emergency department (ED) and hospital burden of celiac disease: 2006–2011 [abstract]. Am J Gastroenterol. 2015;110(suppl 1):S997–8. https://doi.org/10.1038/ajg.2015.280.CrossRef

29.

Bhuva M, Patel J, Sakthivel GD, Rostami K, Marsh MN, Johnson MW. The outpatient burden of coeliac disease on a district general hospital: an 11 year retrospective review [abstract no. PWE-138]. Gut. 2017;66:A196-A7. https://doi.org/10.1136/gutjnl-2017-314472.383.CrossRef

30.

Garrod N, Agbamu J, Barrett C, Holt S. Audit of annual blood tests for children with coeliac disease [abstract no. G235(P)]. Arch Dis Child. 2017;102:A92–3. https://doi.org/10.1136/archdischild-2017-313087.230.CrossRef

31.

Johansson K, Malmberg Hård Af Segerstad E, Mårtensson H, Agardh D. Dietitian visits were a safe and cost-effective form of follow-up care for children with celiac disease. Acta Paediatr. https://doi.org/10.1111/apa.14411 (Epub 2018 May 21).

32.

Vriezinga S, Borghorst A, van den Akker-van Marle E, Benninga M, George E, Hendriks D, et al. E-healthcare for celiac disease—a multicenter randomized controlled trial. J Pediatr. 2018;195(154–60):e7. https://doi.org/10.1016/j.jpeds.2017.10.027.CrossRef

33.

Lee AR, Ng DL, Zivin J, Green PH. Economic burden of a gluten-free diet. J Hum Nutr Diet. 2007;20(5):423–30. https://doi.org/10.1111/j.1365-277X.2007.00763.x.CrossRefPubMed

34.

Singh J, Whelan K. Limited availability and higher cost of gluten-free foods. J Hum Nutr Diet. 2011;24(5):479–86. https://doi.org/10.1111/j.1365-277X.2011.01160.x.CrossRefPubMed

35.

Fry L, Madden AM, Fallaize R. An investigation into the nutritional composition and cost of gluten-free versus regular food products in the UK. J Hum Nutr Diet. 2018;31(1):108–20. https://doi.org/10.1111/jhn.12502.CrossRefPubMed

36.

Panagiotou S, Kontogianni MD. The economic burden of gluten-free products and gluten-free diet: a cost estimation analysis in Greece. J Hum Nutr Diet. 2017;30(6):746–52. https://doi.org/10.1111/jhn.12477.CrossRefPubMed

37.

Namatovu F, Strandh M, Ivarsson A, Nilsson K. Effect of childhood coeliac disease on ninth grade school performance: evidence from a population-based study. Arch Dis Child. 2018;103(2):143–8. https://doi.org/10.1136/archdischild-2017-312830.CrossRefPubMed

38.

Esteve M, Rosinach M, Llordés M, Calpe J, Montserrat G, Pujals M, et al. Case-finding in primary care for coeliac disease: accuracy and cost-effectiveness of a rapid point-of-care test. United Eur Gastroenterol J. 2018. https://doi.org/10.1177/2050640618761700.CrossRef

39.

Gonzalez DA, de Armas LG, Rodriguez IM, Almeida AA, Garcia MG, Gannar F, et al. Strategies to improve the efficiency of celiac disease diagnosis in the laboratory. J Immunol Methods. 2017;449:62–7. https://doi.org/10.1016/j.jim.2017.07.007.CrossRefPubMed

40.

Herrod PJJ, Lund JN. Random duodenal biopsy to exclude coeliac disease as a cause of anaemia is not cost-effective and should be replaced with universally performed pre-endoscopy serology in patients on a suspected cancer pathway. Tech Coloproctol. 2018;22(2):121–4. https://doi.org/10.1007/s10151-018-1756-7.CrossRefPubMedPubMedCentral

41.

Paul SP, Sandhu BK, Spray CH, Basude D, Ramani P. Evidence supporting serology-based pathway for diagnosing celiac disease in asymptomatic children from high-risk groups. J Pediatr Gastroenterol Nutr. 2018;66(4):641–4. https://doi.org/10.1097/MPG.0000000000001757.CrossRefPubMed

42.

Scoglio R, Trifiro G, Sandullo A, Marangio G, D’Agate C, Costa S, et al. Diagnostic yield of 2 strategies for adult celiac disease identification in primary care. J Clin Gastroenterol. 2017. https://doi.org/10.1097/MCG.0000000000000962.CrossRef

43.

Skrabl-Baumgartner A, Christine Hauer A, Erwa W, Jahnel J. HLA genotyping as first-line screening tool for coeliac disease in children with juvenile idiopathic arthritis. Arch Dis Child. 2017;102(7):607–11. https://doi.org/10.1136/archdischild-2016-311544.CrossRefPubMed

44.

Wu J, So H, Klarenbach S, Huynh H, Chen M, Shirton L, et al. Cost analysis of serological versus biopsy-proven diagnosis of pediatric celiac disease. J Pediatr Gastroenterol Nutr. 2017;65:S97–8. https://doi.org/10.1097/MPG.0000000000001805.CrossRef

45.

Alessandrini S, Giacomoni E, Muccioli F. Mass population screening for celiac disease in children: the experience in Republic of San Marino from 1993 to 2009. Ital J Pediatr. 2013;39:67. https://doi.org/10.1186/1824-7288-39-67.CrossRefPubMedPubMedCentral

46.

Burger JP, Meijer JW, Wahab PJ. Routine duodenal biopsy to screen for coeliac disease is not effective. Neth J Med. 2013;71(6):308–12.PubMed

47.

Chogle A, Saps M. Yield and cost of performing screening tests for constipation in children. Can J Gastroenterol. 2013;27(12):e35–8.CrossRef

48.

Kotha S, Holohan C, Gera A, Loganayagam A. D2 biopsies in weight loss referrals-is it necessary and cost effective? [abstract no. PTH-032]. Gut. 2015;64(suppl1):A420. https://doi.org/10.1136/gutjnl-2015-309861.920.CrossRef

49.

Kotha S, McLaren K, Holohan C, McNair A. Coeliac disease screening in ‘2 week wait’ patients: biopsy or serology? [abstract no. PTU-162]. Gut. 2015;64(suppl 1):A134–5. https://doi.org/10.1136/gutjnl-2015-309861.277.CrossRef

50.

Nelsen EM, Lochmann-Bailkey A, Pfau P, Gopal DV, Benson ME. Low yield and high cost of gastric and duodenal biopsies for investigation of symptoms of abdominal pain during routine esophagogastroduodenoscopy [abstract no. 701]. Gastrointest Endosc. 2016;83(5 Suppl 1):AB164.CrossRef

51.

Olen O, Gudjonsdottir AH, Browaldh L, Hessami M, Elvin K, Liedberg AS, et al. Antibodies against deamidated gliadin peptides and tissue transglutaminase for diagnosis of pediatric celiac disease. J Pediatr Gastroenterol Nutr. 2012;55(6):695–700. https://doi.org/10.1097/MPG.0b013e3182645c54.CrossRefPubMed

52.

Sandhu B, Paul S. Should the new ESPGHAN guidelines on diagnosing celiac disease be modified to apply to asymptomatic children? [abstract]. J Pediatr Gastroenterol Nutr. 2016;63(suppl 2):S311–2. https://doi.org/10.1097/01.mpg.0000503536.79797.66.CrossRef

53.

Sheahan K, Wallace E, Cullen G. Is anti-tTG alone sufficient for diagnosis of celiac disease? [abstract]. Irish J Med Sci. 2015;184(7 suppl 1):S320. https://doi.org/10.1007/s11845-015-1321-6.CrossRef

54.

Teriaky A, AlNasser A, McLean C, Gregor J, Yan B. The utility of endoscopic biopsies in patients with normal upper endoscopy. Can J Gastroenterol Hepatol. 2016;2016:3026563. https://doi.org/10.1155/2016/3026563.CrossRefPubMedPubMedCentral

55.

Broide E, Matalon S, Kriger-Sharabi O, Richter V, Shirin H, Leshno M. Cost effectiveness of routine duodenal biopsies in iron deficiency anemia. World J Gastroenterol. 2016;22(34):7813–23. https://doi.org/10.3748/wjg.v22.i34.7813.CrossRefPubMedPubMedCentral

56.

Dorn SD, Matchar DB. Cost-effectiveness analysis of strategies for diagnosing celiac disease. Dig Dis Sci. 2008;53(3):680–8. https://doi.org/10.1007/s10620-007-9939-5.CrossRefPubMed

57.

Park KT, Tsai R, Wang L, Khavari N, Bachrach L, Bass D. Cost-effectiveness of universal serologic screening to prevent nontraumatic hip and vertebral fractures in patients with celiac disease. Clin Gastroenterol Hepatol. 2013;11(6):645–53. https://doi.org/10.1016/j.cgh.2012.12.037.CrossRefPubMedPubMedCentral

58.

Yang JJ, Thanataveerat A, Green PH, Lebwohl B. Cost effectiveness of routine duodenal biopsy analysis for celiac disease during endoscopy for gastroesophageal reflux. Clin Gastroenterol Hepatol. 2015;13(8):1437–43. https://doi.org/10.1016/j.cgh.2015.03.022.CrossRefPubMedPubMedCentral

59.

Greco L, Timpone L, Abkari A, Abu-Zekry M, Attard T, Bouguerra F, et al. Burden of celiac disease in the Mediterranean area. World J Gastroenterol. 2011;17(45):4971–8. https://doi.org/10.3748/wjg.v17.i45.4971.CrossRefPubMedPubMedCentral

60.

Walker AJ, Curtis HJ, Bacon S, Croker R, Goldacre B. Trends, geographical variation and factors associated with prescribing of gluten-free foods in English primary care: a cross-sectional study. BMJ Open. 2018;8(3):e021312. https://doi.org/10.1136/bmjopen-2017-021312.CrossRefPubMedPubMedCentral

61.

Pearson L, Cohn AH, Nicholas F, Smith R. Laboratory testing for celiac disease at the university of vermont medical center: testing practices, utilization, and evidence for a standardized approach to diagnosis. Gastroenterology. 2017;152(5):S223–4.CrossRef

62.

Long KH, Rubio-Tapia A, Wagie AE, Melton LJ, Lahr BD, Dyke CTV, et al. The economics of coeliac disease: a population-based study. Aliment Pharmacol Ther. 2010;32(2):261–9. https://doi.org/10.1111/j.1365-2036.2010.04327.x.CrossRefPubMedPubMedCentral

63.

Saneian H, Gorgani AM. Diagnostic value of serologic tests in celiac screening. Int J Prev Med. 2012;3(Suppl 1):S58–63.PubMedPubMedCentral

64.

Norstrom F, Ivarsson A, Lindholm L, Carlsson A, Danielsson L, Hogberg L, et al. Parents’ willingness to pay for coeliac disease screening of their child. J Pediatr Gastroenterol Nutr. 2011;52(4):452–9. https://doi.org/10.1097/MPG.0b013e3182037efd.CrossRefPubMed

65.

Ludvigsson JF, Bai JC, Biagi F, Card TR, Ciacci C, Ciclitira PJ, et al. Diagnosis and management of adult coeliac disease: guidelines from the British Society of Gastroenterology. Gut. 2014;63(8):1210–28. https://doi.org/10.1136/gutjnl-2013-306578.CrossRefPubMedPubMedCentral

66.

Husby S, Koletzko S, Korponay-Szabo IR, Mearin ML, Phillips A, Shamir R, et al. European Society for Pediatric Gastroenterology, Hepatology, and Nutrition guidelines for the diagnosis of coeliac disease. J Pediatr Gastroenterol Nutr. 2012;54(1):136–60. https://doi.org/10.1097/MPG.0b013e31821a23d0.CrossRefPubMed

67.

Ludvigsson JF, Card TR, Kaukinen K, Bai J, Zingone F, Sanders DS, et al. Screening for celiac disease in the general population and in high-risk groups. United Eur Gastroenterol J. 2015;3(2):106–20. https://doi.org/10.1177/2050640614561668.CrossRef

68.

Raivio T, Kaukinen K, Nemes E, Laurila K, Collin P, Kovacs JB, et al. Self transglutaminase-based rapid coeliac disease antibody detection by a lateral flow method. Aliment Pharmacol Ther. 2006;24(1):147–54. https://doi.org/10.1111/j.1365-2036.2006.02957.x.CrossRefPubMed

69.

Nemec G, Ventura A, Stefano M, Di Leo G, Baldas V, Tommasini A, et al. Looking for celiac disease: diagnostic accuracy of two rapid commercial assays. Am J Gastroenterol. 2006;101(7):1597–600. https://doi.org/10.1111/j.1572-0241.2006.00597.x.CrossRefPubMed

70.

Korponay-Szabo IR, Szabados K, Pusztai J, Uhrin K, Ludmany E, Nemes E, et al. Population screening for coeliac disease in primary care by district nurses using a rapid antibody test: diagnostic accuracy and feasibility study. BMJ. 2007;335(7632):1244–7. https://doi.org/10.1136/bmj.39405.472975.80.CrossRefPubMedPubMedCentral

71.

Popp A, Jinga M, Jurcut C, Balaban V, Bardas C, Laurila K, et al. Fingertip rapid point-of-care test in adult case-finding in coeliac disease. BMC Gastroenterol. 2013;13:115. https://doi.org/10.1186/1471-230X-13-115.CrossRefPubMedPubMedCentral

72.

Popp A, Mihu M, Munteanu M, Ene A, Dutescu M, Colcer F, et al. Prospective antibody case finding of coeliac disease in type-1 diabetes children: need of biopsy revisited. Acta Paediatr. 2013;102(3):e102–6. https://doi.org/10.1111/apa.12117.CrossRefPubMed

73.

Mooney PD, Kurien M, Sanders DS. Simtomax, a novel point of care test for coeliac disease. Expert Opin Med Diagn. 2013;7(6):645–51. https://doi.org/10.1517/17530059.2013.836179.CrossRefPubMed

74.

Mooney PD, Wong SH, Johnston AJ, Kurien M, Avgerinos A, Sanders DS. Increased detection of celiac disease with measurement of deamidated gliadin peptide antibody before endoscopy. Clin Gastroenterol Hepatol. 2015;13(7):1278 e1–1284 e1. https://doi.org/10.1016/j.cgh.2015.01.010.CrossRef

75.

Lau MS, Mooney PD, White WL, Rees MA, Wong SH, Kurien M, et al. The role of an IgA/IgG-deamidated gliadin peptide point-of-care test in predicting persistent villous atrophy in patients with celiac disease on a gluten-free diet. Am J Gastroenterol. 2017;112(12):1859–67. https://doi.org/10.1038/ajg.2017.357.CrossRefPubMed

76.

Green PH, Neugut AI, Naiyer AJ, Edwards ZC, Gabinelle S, Chinburapa V. Economic benefits of increased diagnosis of celiac disease in a national managed care population in the United States. J Insur Med. 2008;40(3–4):218–28.PubMed

77.

Barnett SB, Nurmagambetov TA. Costs of asthma in the United States: 2002–2007. J Allergy Clin Immunol. 2011;127(1):145–52. https://doi.org/10.1016/j.jaci.2010.10.020.CrossRefPubMed

78.

Kawatkar AA, Jacobsen SJ, Levy GD, Medhekar SS, Venkatasubramaniam KV, Herrinton LJ. Direct medical expenditure associated with rheumatoid arthritis in a nationally representative sample from the medical expenditure panel survey. Arthritis Care Res (Hoboken). 2012;64(11):1649–56. https://doi.org/10.1002/acr.21755.CrossRef

79.

American Diabetes Association. Economic costs of diabetes in the U.S. in 2012. Diabetes Care. 2013;36:1033–46.CrossRef

80.

Eigner W, Bashir K, Primas C, Kazemi-Shirazi L, Wrba F, Trauner M, et al. Dynamics of occurrence of refractory coeliac disease and associated complications over 25 years. Aliment Pharmacol Ther. 2017;45(2):364–72. https://doi.org/10.1111/apt.13867.CrossRefPubMed

81.

Department of Health and Social Care, United Kingdom. Published in London, United Kingdom. https://www.gov.uk/government/news/consultation-launched-on-prescribing-of-gluten-free-foods. Accessed 5 May 2017.

82.

Coeliac Organization United Kingdom. Gluten-free diet and lifestyle: prescriptions. 2018. https://www.coeliac.org.uk/gluten-free-diet-and-lifestyle/prescriptions/. Accessed 12 Jul 2018.

83.

Aggarwal A, Cook AJ, Jiao J, Seguin RA, Vernez Moudon A, Hurvitz PM, et al. Access to supermarkets and fruit and vegetable consumption. Am J Public Health. 2014;104(5):917–23. https://doi.org/10.2105/AJPH.2013.301763.CrossRefPubMedPubMedCentral

84.

Malterre T. Digestive and nutritional considerations in celiac disease: could supplementation help? Altern Med Rev. 2009;14(3):247–57.PubMed

85.

Robson K, Alizart M, Martin J, Nagel R. Coeliac patients are undiagnosed at routine upper endoscopy. PLoS One. 2014;9(3):e90552. https://doi.org/10.1371/journal.pone.0090552.CrossRefPubMedPubMedCentral

86.

Greuter TSA, Frei P, et al. Substantial proportion of celiac disease patients is misleadingly diagnosed based on serology only-diagnostic and therapeutic experience from a real-life setting in Switzerland [abstract]. United Eur Gastroenterol J. 2015;2(Suppl 1):A679.

87.

Charalampopoulos D, Panayiotou J, Chouliaras G, Zellos A, Kyritsi E, Roma E. Determinants of adherence to gluten-free diet in Greek children with coeliac disease: a cross-sectional study. Eur J Clin Nutr. 2013;67(6):615–9. https://doi.org/10.1038/ejcn.2013.54.CrossRefPubMed

Title: Systematic Literature Review of the Economic Burden of Celiac Disease
Authors: Elizabeth S. Mearns
Aliki Taylor
Talia Boulanger
Kelly J. Craig
Michele Gerber
Daniel A. Leffler
Jennifer Drahos
David S. Sanders
Benjamin Lebwohl
Publication date: 01-01-2019
Publisher: Springer International Publishing
Published in: PharmacoEconomics / Issue 1/2019
Print ISSN: 1170-7690
Electronic ISSN: 1179-2027
DOI: https://doi.org/10.1007/s40273-018-0707-5

2024 ASCO Annual Meeting

Springer Medicine

Systematic Literature Review of the Economic Burden of Celiac Disease

Abstract

Background

Objective

Methods

Results

Conclusions

2024 ASCO Annual Meeting

Springer Medicine

Abstract

Background

Objective

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 1/2019

Trusting the Results of Model-Based Economic Analyses: Is there a Pragmatic Validation Solution?

The Impact of Moving from EQ-5D-3L to -5L in NICE Technology Appraisals

One Method, Many Methodological Choices: A Structured Review of Discrete-Choice Experiments for Health State Valuation

Pembrolizumab for Previously Treated Advanced or Metastatic Urothelial Cancer: An Evidence Review Group Perspective of a NICE Single Technology Appraisal

Health State Utilities for Acute Myeloid Leukaemia: A Time Trade-off Study

Exploring Different Strategies of Assessing the Economic Impact of Multiple Diabetes-Associated Complications and Their Interactions: A Large Claims-Based Study in Germany